Related to this, treatment with a BDK inhibitor BT2, which increases BCAA catabolism, restores the decrease in insulin sensitivity normally associated with elevated BCAA/BCKAs, suggesting that increasing BCAA catabolism may help against obesity-induced insulin resistance (Zhou et al., 2019). The gene discussed is BCKDK; the disease is obesity due to melanocortin 4 receptor deficiency.